Auger Emitting [<sup>161</sup>Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis. [PDF]
Rosar F +7 more
europepmc +1 more source
Assessment of Early Cardiotoxicity and Cardiac Dysfunction of Radioligand Therapy in Patients with Neuroendocrine Tumors. [PDF]
Jóźwik-Plebanek K +9 more
europepmc +1 more source
Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer. [PDF]
Suh M, O JH.
europepmc +1 more source
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy. [PDF]
Kramer CS +5 more
europepmc +1 more source
PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer. [PDF]
Wang X +11 more
europepmc +1 more source
Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. [PDF]
Ghaemi B +9 more
europepmc +1 more source
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP. [PDF]
Lee EJ +5 more
europepmc +1 more source
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. [PDF]
Beltran H +4 more
europepmc +1 more source
Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials. [PDF]
Palihati M, Das JP, Yeh R, Capaccione K.
europepmc +1 more source
Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy. [PDF]
Schenzle C.
europepmc +1 more source

